NPC(SH:600713) Zheng Quan Zhi Xing·2025-06-09 10:23Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. is issuing convertible bonds to unspecified investors, with a total amount of RMB 1,081,491,000, to be used for various investment projects [3][16][24] Group 1: Issuance Details - The company has received approval from its board and regulatory authorities to issue 10,814,910 convertible bonds, each with a face value of RMB 100 [3][4] - The total amount raised from this issuance is RMB 1,069,040,922.31 after deducting issuance costs [3][16] - The bonds will have a maturity period of six years from the date of issuance [5][16] Group 2: Bond Terms - The coupon rates for the bonds are set at 0.20% for the first year and 0.40% for the second year, with further rates to be determined for subsequent years [5][16] - The initial conversion price for the bonds is set at RMB 5.29 per share, subject to adjustments based on specific corporate actions [8][24] - The bonds will be redeemable at 108% of the face value after maturity, and the company has the right to redeem them under certain conditions during the conversion period [9][10] Group 3: Use of Proceeds - The net proceeds from the bond issuance will be allocated to various investment projects totaling RMB 118,665,520, with the company covering any shortfall [16][24] - The company plans to ensure that the timing of fund availability aligns with the project implementation schedule [16] Group 4: Shareholder Rights and Adjustments - Existing shareholders will have preferential rights to subscribe to the bonds based on their holdings as of the record date [14][16] - The company will adjust the conversion price of the bonds in response to stock dividends, capital increases, or other equity changes [8][24] - The company has established a dedicated account for the repurchase of restricted stock as part of its incentive plan, which will not significantly impact the bondholders' rights [19][24]